Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.

Branco JC, Cherin P, Montagne A, Bouroubi A; Multinational Coordinator Study Group.

J Rheumatol. 2011 Jul;38(7):1403-12. doi: 10.3899/jrheum.101025. Epub 2011 Apr 1.

PMID:
21459941
2.

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y.

Arthritis Rheum. 2010 Sep;62(9):2745-56. doi: 10.1002/art.27559.

3.

A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.

Branco JC, Zachrisson O, Perrot S, Mainguy Y; Multinational Coordinator Study Group.

J Rheumatol. 2010 Apr;37(4):851-9. doi: 10.3899/jrheum.090884. Epub 2010 Feb 15.

PMID:
20156949
4.

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.

Clin Ther. 2008 Nov;30(11):1988-2004. doi: 10.1016/j.clinthera.2008.11.009. Erratum in: Clin Ther. 2009 Feb;31(2):446. Clin Ther. 2009 Jul;31(7):1617.

PMID:
19108787
5.

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH.

J Rheumatol. 2009 Feb;36(2):398-409. doi: 10.3899/jrheum.080734. Erratum in: J Rheumatol. 2009 Mar;36(3):661.

PMID:
19132781
6.

Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.

Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM.

Pain Med. 2010 Feb;11(2):180-94. doi: 10.1111/j.1526-4637.2009.00755.x. Epub 2009 Dec 9.

7.

A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.

Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ.

Pain Pract. 2011 Mar-Apr;11(2):120-31. doi: 10.1111/j.1533-2500.2010.00403.x.

PMID:
20642487
8.

Milnacipran: in fibromyalgia.

Chwieduk CM, McCormack PL.

Drugs. 2010;70(1):99-108. doi: 10.2165/11202810-000000000-00000.

PMID:
20030428
9.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

OliƩ JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
10.

Efficacy of milnacipran in patients with fibromyalgia.

Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ.

J Rheumatol. 2005 Oct;32(10):1975-85.

PMID:
16206355
11.

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.

Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG.

Hum Psychopharmacol. 2004 Oct;19 Suppl 1:S27-35.

PMID:
15378666
12.

Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.

Arnold LM, Palmer RH, Gendreau RM, Chen W.

Psychosomatics. 2012 Jul-Aug;53(4):371-9. doi: 10.1016/j.psym.2012.02.005. Epub 2012 Jun 6.

PMID:
22677218
13.

A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia.

Arnold LM, Palmer RH, Ma Y.

Clin J Pain. 2013 Dec;29(12):1021-8. doi: 10.1097/AJP.0b013e31828440ab.

PMID:
23446068
14.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
15.

Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.

Isaac MT, Isaac MB, Gallo F, Tournoux A.

Hum Psychopharmacol. 2003 Dec;18(8):595-601.

PMID:
14696018
16.

Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study.

Trugman JM, Palmer RH, Ma Y.

Curr Med Res Opin. 2014 Apr;30(4):589-97. doi: 10.1185/03007995.2013.861812. Epub 2013 Nov 20.

PMID:
24188161
17.

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.

Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.

Arthritis Rheum. 2004 Sep;50(9):2974-84.

18.

Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial.

Staud R, Lucas YE, Price DD, Robinson ME.

J Pain. 2015 Aug;16(8):750-9. doi: 10.1016/j.jpain.2015.04.010. Epub 2015 May 19.

PMID:
25998206
20.

Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.

Mease PJ, Palmer RH, Wang Y.

J Clin Rheumatol. 2014 Jun;20(4):195-202. doi: 10.1097/RHU.0000000000000103.

PMID:
24847745
Items per page

Supplemental Content

Write to the Help Desk